| Name | BMS-309403 |
| Description | BMS309403 is a potent and selective inhibitor of adipocyte fatty acid binding protein aFABP. It improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. It interacts with the fatty acid binding pocket inside the protein and competitively inhibits the binding of endogenous fatty acids. |
| In vitro | Treatment with BMS309403 significantly reduced MCP-1 production in THP-1 macrophages in a dose- and time-dependent manner.[1] |
| In vivo | METHODS: 3 weeks after the onset of diabetes, mice were orally treated with BMS309403 (40 mg/kg, daily) for 3 weeks. During treatment, monitor blood sugar levels.
RESULTS BMS309403 can significantly reduce the protein expression of FABP4 in mouse retinal tissue and partially reduce blood glucose levels in mice. [2] |
| Storage | Keep away from moisture | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 20 mM, Heating is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.21 mM), Sonication is recommended.
DMSO : 255 mg/mL (537.35 mM), Sonication is recommended.
|
| Keywords | uptake | selective | oral | Inhibitor | inhibit | glucose | function | Fatty acid-binding protein | FABP5 | FABP4 | FABP3 | FABP | endothelial | BMS-309403 | BMS309403 | BMS 309403 |
| Inhibitors Related | (Iso)-SBFI-26 | 12-NBD Stearate | FABPs ligand 6 | Eriocalyxin B | STK-15 | FABP4-IN-4 | FABP4/5-IN-2 | BMS-309403 sodium | HM-50316 | ISX-1 | FABP4/5-IN-5 | HTS01037 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | Multi-Target Compound Library | Inhibitor Library | NO PAINS Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |
United States
